Wnt5a诱导ROR1招募DOCK2激活慢性淋巴细胞白血病中的Rac1/2
研究发现Wnt5a可诱导慢性淋巴细胞白血病(CLL)细胞中ROR1与DOCK2形成复合物并激活Rac1/2,该效应可被抗ROR1单抗cirmtuzumab阻断;沉默DOCK2或ROR1-PRD结构域P808A突变则消除上述效应及细胞生长优势。
要点
- Wnt5a诱导ROR1与DOCK2复合激活Rac1/2,cirmtuzumab可阻断该效应。
- 沉默DOCK2消除Wnt5a诱导的Rac1/2激活及CLL细胞增殖增强。
- ROR1-PRD的P808A突变使其无法招募DOCK2,且转染该突变体的MEC1细胞无生长优势。
核心结论
- Wnt5a诱导ROR1招募DOCK2对增强CLL细胞增殖能力至关重要,可能解释ROR1高表达CLL患者疾病进展倾向增加。
研究设计与样本
- 研究采用CLL细胞及CLL细胞系MEC1,通过沉默DOCK2、构建ROR1截短体及P→A点突变体(P784A、P808A、P826A、P841A)进行功能验证。
主要发现
- Wnt5a可诱导ROR1与DOCK2复合并激活Rac1/2,该效应可被cirmtuzumab阻断。
- 沉默DOCK2特异性削弱Wnt5a诱导的Rac1/2激活及CLL细胞增殖增强。
- ROR1胞质富脯氨酸结构域(PRD)是Wnt5a诱导ROR1与DOCK2复合及Rac1/2激活所必需。
- ROR1P808A突变体无法响应Wnt5a招募DOCK2。
- 转染ROR1P808A的MEC1细胞较不表达ROR1的MEC1细胞无生长优势,而转染野生型ROR1或ROR1 P784A、P826A、P841A突变体的MEC1细胞则具有生长优势。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an oncoembryonic protein expressed on chronic lymphocytic leukemia (CLL) that can serve as a receptor for Wnt5a, which can promote leukemia cell migration, proliferation, and survival. We found Wnt5a could induce ROR1 to complex with DOCK2 (dedicator of cytokinesis 2) and induce activation of Rac1/2; these effects could be blocked by cirmtuzumab, a humanized anti-ROR1 monoclonal antibody. We find that silencing DOCK2 specifically impaired the capacity of Wnt5a to induce activation of Rac1/2 or enhance CLL cell proliferation. We generated truncated forms of ROR1 and found the cytoplasmic proline-rich domain (PRD) of ROR1 was required for Wnt5a to induce ROR1 to complex with DOCK2 and activate Rac1/2 in the CLL cell-line MEC1. We introduced single amino acid substitutions of proline (P) to alanine (A) in the ROR1-PRD at potential binding sites for the Src-homology 3 domain of DOCK2. In contrast to wild-type ROR1, or other ROR1 P→A variants, ROR1P808A was unable to recruit DOCK2 in response to Wnt5a. Moreover, unlike MEC1 cells transfected with wild-type ROR1 or ROR1 with P→A substitutions at positions 784, 826, or 841, MEC1 cells transfected to express ROR1P808A did not have a growth advantage over MEC1 cells that do not express ROR1. This study reveals that the recruitment of DOCK2 may be critical for the capacity of Wnt5a to enhance CLL proliferation, which may contribute to the observed increased tendency for disease progression in patients who have CLL cells that express high levels of ROR1.
引用
- Hasan MK, Yu J, Widhopf GF, et al. Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia. Blood. 2018. PMID: 29678828. doi:10.1182/blood-2017-12-819383
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。